Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMRs), and Connected Persons under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions.
Transaction details include:
- Share Price: 1,268.00 pence per Ordinary Share and $38.74 per American Depositary Share (ADS).
- Transaction Type: Notional acquisition of shares following the re-investment of dividends paid on October 1, 2015.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It details specific share acquisitions by the following individuals:
- Directors/PDMRs: Sir Andrew Witty, Dr M M Slaoui, Mr S Dingemans, Mr R G Connor, Mr N Hirons, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Mr D E Troy, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Connected Persons: Dr K Slaoui and Mrs K Thomson.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Plan holdings that vest following the end of the relevant measurement period. The notification complies with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Investor Verification Checklist
- Verify the vesting schedule and measurement period for the 2009 Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares issued under the plan to assess potential dilution.
- Review the dividend payment date (October 1, 2015) and amount to validate the basis for the notional re-investment.
- Check subsequent filings for the actual vesting and payout of these notional shares.